ASENT 2021
ANNUAL MEETING
February 22-25, 2021
Virtual Neuroscience and Neurotherapeutics Conference

ADVANCE PROGRAM
A Quick Look at ASENT 2021

Annual Meeting Overview
ASENT 2021 is the premier neurotherapeutics conference where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions.

MEETING DETAILS
ASENT 2021 Meeting Dates
Monday, February 22 - Thursday, February 25, 2021

VIRTUAL FORMAT
Abstract Submissions
Open through December 21, 2020
https://www.eventbrite.com/e/126563507859

REGISTRATION IS OPEN
Annual Meeting Registration Deadline
February 15, 2021
https://www.eventbrite.com/e/125915487613

Meeting Location
ONLINE

WHO ATTENDS
Clinician-investigators
Neuroscientists
Industry research scientists
Clinical and Experimental Neuroscience Trainees
Advocacy Group Leaders
Chief Medical Officers
CEOs
Founders
Funders
Investors
Innovation Centers
Journal Editors
Drug and Device Companies
Communication Companies
Health Systems
Chairs of Neurology
Executive Directors
FDA
NINDS
NIMH
NIA
All ARE WELCOME!

WHAT IS ASENT?
The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.
Register for ASENT 2021

Online Registration
In light of these unique times, the American Society for Experimental Neurotherapeutics has decided to make the 2021 Annual Meeting free to all attendees. Don’t miss this opportunity to access outstanding content, poster sessions and pipeline presentations.

FREE TO REGISTERED ATTENDEES

Register Today: www.eventbrite.com/e/125915487613
# ASENT 2021 Schedule at a Glance

## Monday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:35am</td>
<td>Symposium</td>
<td>COVID-19 and the nervous system as a basic medical and therapeutic challenge</td>
</tr>
<tr>
<td>11:35am - 11:45am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:45am - 1:00pm</td>
<td>Concurrent Symposia</td>
<td>Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease</td>
</tr>
<tr>
<td>1:00pm - 1:15pm</td>
<td>Comments from President</td>
<td></td>
</tr>
<tr>
<td>1:15pm - 1:30pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>1:30pm - 2:00pm</td>
<td>Sponsored Symposium</td>
<td></td>
</tr>
<tr>
<td>2:00pm - 3:00pm</td>
<td>Poster Presentations</td>
<td></td>
</tr>
</tbody>
</table>

## Tuesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td>Concurrent Symposia</td>
<td>New and Emerging Therapeutics for Epilepsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dystonia: Genetics, pathophysiology, new targets and treatment</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:30am - 12:45pm</td>
<td>Pipeline</td>
<td>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>Comments from President</td>
<td></td>
</tr>
<tr>
<td>1:00pm - 2:00pm</td>
<td>Sponsored Symposium</td>
<td></td>
</tr>
<tr>
<td>2:00pm - 3:00pm</td>
<td>Poster Presentations</td>
<td></td>
</tr>
</tbody>
</table>
## ASENT 2021 SCHEDULE AT A GLANCE

### WEDNESDAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Concurrent Symposia</th>
<th>Epigenetics in Neurodegenerative Disorders</th>
<th>Emerging therapeutics in NeuroOncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30am - 12:45pm</td>
<td>Pipeline</td>
<td>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</td>
<td></td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>Comments from President</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm - 2:00pm</td>
<td>Sponsored Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00pm - 3:00pm</td>
<td>Poster Presentations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### THURSDAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Concurrent Symposia</th>
<th>Brain Organoids as Models of Neurological Disorders and Treatment</th>
<th>Parkinson's Disease: New Approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30am - 12:45pm</td>
<td>Pipeline</td>
<td>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</td>
<td></td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>Meeting Conclusion and Comments from President</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm - 2:00pm</td>
<td>Sponsored Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00pm - 3:00pm</td>
<td>Poster Presentations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### PRESIDENTIAL SYMPOSIUM: COVID-19 and the nervous system as a basis medical and therapeutic challenge

**Chairs:**
- Thomas Sutula, MD, PhD, University of Wisconsin
- C. Anthony Altar, PhD, Splice Therapeutics
- Carole Burns, PhD

Symposium to cover 1918 flu pandemic, the 2020 COVID-19 pandemic and neurological consequences. Stroke, olfactory (anosmia) and gustatory deficits and other neurological complications result from COVID-19 infection. The delayed appearance of postencephalitic Parkinsonism in people surviving the 1918 flu and those contracting encephalitis lethargica around the same time indicate hidden, protracted risks may await those who survive viral pandemics. These topics and an update of neurological complications of COVID-19 will be reviewed in this symposium.

### FACULTY

#### 10:00am - 10:30am
**KEYNOTE PRESENTATION:**
Neurological Consequences of Viral Pandemics including COVID-19 | Avindra Nath, MD, National Institute of Neurological Disorders and Stroke

#### 10:30am - 10:40am
Live Q&A with KEYNOTE SPEAKER

#### 10:40am - 10:45am
BREAK

#### 10:45am - 11:05am
Serena S. Spudich, MD, Neuroinfectious Diseases and Global Neurology, Yale University School of Medicine

#### 11:05am - 11:25am
Arvid Edén, MD, Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg

#### 11:25am - 11:35am
Live Faculty Panel Discussion and Q&A

#### 11:35am - 11:45am
BREAK

#### 11:45pm - 1:00pm
**Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics**

- **Chairs:**
  - Bennett Lavenstein, MD, Children's National
  - Sharon Tamir, Karyopharm

Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer's Disease neurotherapeutics.

**RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease**

- **Chairs:**
  - Ann-Marie Broome, MBA, PhD, NINDS
  - Lloyd Mitchell, MD, RetroTherapy

Discussion of gene editing as an advancement in gene therapy including DNA and RNA editing, Molecular mechanisms, clinical potentials of genome editing systems, and therapeutic development in neurological disorders.

#### 11:45am - 12:05pm
Advances in Alzheimer's Disease and Related Dementia Research | Eliezer Masliah, MD, National Institute on Aging

#### 12:05pm - 12:25pm
Leveraging Dominantly Inherited Alzheimer Disease for Current and Future Alzheimer Therapeutics | Eric McDade, DO, Washington University School of Medicine in St. Louis

#### 12:25pm - 12:45pm
Barriers to success /opportunities in Alzheimer's on the basis of prior or forthcoming trials | Dennis Selkoe, MD, Harvard Medical School and Brigham and Women's Hospital

#### 12:45pm - 1:00pm
Live Faculty Panel Discussion and Q&A

#### 1:00pm - 1:15pm
Closing comments from ASENT President
### Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy

**Chairs:**
Aditya Joshi, MD, University of Pennsylvania  
Danilo Vitorovic, MD, University of Vermont  
Gail Farfel, PhD, Zogenix

There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy.

**Faculty**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 10:20am</td>
<td>Natural Language Processing of EEG Reports to Learn Seizure Onsets</td>
</tr>
<tr>
<td>10:20am - 11:40am</td>
<td>Discovering Genotype-Phenotype Correlations Hidden in the EMR</td>
</tr>
<tr>
<td>10:40am - 11:00am</td>
<td>Applying artificial intelligence to epilepsy care: from scanner to bedside</td>
</tr>
<tr>
<td>11:00am - 11:15am</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

### Dystonia: Genetics, pathophysiology, new targets and treatment

**Chairs:**
Stewart Factor, MD, Emory University  
Debra Ehrlich, MD, NINDS

Faculty will address genes and mechanisms in Dystonia, pathophysiology specific to dystonia as well as, new targets and treatments to address the disease state.

**Faculty**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 10:20am</td>
<td>Dystonia Genes &amp; Mechanisms</td>
</tr>
<tr>
<td>10:20am - 11:40am</td>
<td>Pathophysiology in Dystonia</td>
</tr>
<tr>
<td>10:40am - 11:00am</td>
<td>New Targets and Treatments in Dystonia</td>
</tr>
<tr>
<td>11:00am - 11:15am</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

### PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30am - 12:30pm</td>
<td>6 presentations each day/10 minutes each</td>
</tr>
<tr>
<td>12:30pm - 12:45am</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>Closing comments from ASENT President</td>
</tr>
</tbody>
</table>
### DAY 3 | WEDNESDAY, FEBRUARY 24, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td>Physiological markers and epigenetic risk factors in neurodegenerative disorders</td>
<td>Emerging therapeutics in NeuroOncology</td>
</tr>
<tr>
<td><strong>Chairs:</strong></td>
<td>Amy Chappell, MD, Eliem Suhayl Dhib-Jalbut, MD, UMDNJ-Rutgers</td>
<td>Chairs: Sharon Tamir, Karyopharm</td>
</tr>
<tr>
<td></td>
<td>This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome.</td>
<td>Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases</td>
</tr>
<tr>
<td>10:00am - 10:20am</td>
<td>Multiple sclerosis susceptibility variants exert local and distal effects on the T cell epigenome</td>
<td>Philip deJager, MD, PhD, Columbia University</td>
</tr>
<tr>
<td>10:20am - 11:40am</td>
<td>Physiological markers of stress and aging</td>
<td>David Ziegler, PhD, University of California, San Francisco</td>
</tr>
<tr>
<td>10:40am - 11:00am</td>
<td>Epigenetic regulation of myelination and remyelination</td>
<td>Patrizia Casaccia, MD, PhD, Icahn School of Medicine</td>
</tr>
<tr>
<td>10:00am - 12:30pm</td>
<td>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</td>
<td>6 presentations each day/10 minutes each</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>11:30am - 12:30pm</td>
<td>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</td>
<td>6 presentations each day/10 minutes each</td>
</tr>
<tr>
<td>12:30pm - 12:45am</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>Closing comments from ASENT President</td>
<td>Live Faculty Panel Discussion and Q&amp;A</td>
</tr>
</tbody>
</table>
### DAY 4 | THURSDAY, FEBRUARY 25, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td><strong>Brain Organoids as Models of Neurological Disorders and Treatment</strong></td>
<td><strong>Parkinson's Disease: New Approaches</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> C. Anthony Altar, Splice Therapeutics</td>
<td><strong>Chairs:</strong> Stewart Factor, MD, Emory University</td>
</tr>
<tr>
<td></td>
<td>Amir Tamiz, PhD, NINDS</td>
<td>Debra Ehrlich, MD, NINDS</td>
</tr>
<tr>
<td></td>
<td>Speakers will describe the technology behind creating three-dimensional</td>
<td>Speakers will discuss Stem cells, C-ABL therapy, and exercise in the</td>
</tr>
<tr>
<td></td>
<td>cell clusters that resemble peripheral and central nervous tissue, and</td>
<td>context of Parkinson's Disease therapeutic gaps and developments.</td>
</tr>
<tr>
<td></td>
<td>how these CNS and PNS models show phenotypes consistent with CNS tissue,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and diseases that plagued donors of the progenitor cells used to make</td>
<td></td>
</tr>
<tr>
<td></td>
<td>these cell systems. The use of organoids to evaluate known and novel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>therapeutic agents, including gene therapies, will also be shown.</td>
<td></td>
</tr>
<tr>
<td>10:00am - 10:20am</td>
<td>**Modelling physiology and disease with brain organoids</td>
<td><strong>Stem cells therapy in Parkinson's Disease</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Howard Federoff, MD, PhD, Aspen Neuroscience</td>
</tr>
<tr>
<td>10:20am - 11:40am</td>
<td>**Optimization and scaling of patient-derived brain organoids for disease</td>
<td><strong>Disease modification of Parkinson’s Disease through oral kinase inhibitor therapy</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>phenotyping and drug discovery**</td>
</tr>
<tr>
<td>10:40am - 11:00am</td>
<td>**3D Neuronal Spheroids and Organoids for Disease Modeling and Drug</td>
<td><strong>Therapeutically Beneficial Effects of Exercise on Parkinson’s Disease</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discovery</td>
</tr>
<tr>
<td>11:00am - 11:15am</td>
<td><strong>Live Faculty Panel Discussion and Q&amp;A</strong></td>
<td><strong>Live Faculty Panel Discussion and Q&amp;A</strong></td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</strong></td>
<td></td>
</tr>
<tr>
<td>11:30am - 12:30pm</td>
<td>6 presentations each day/10 minutes each</td>
<td></td>
</tr>
<tr>
<td>12:30pm - 12:45am</td>
<td><strong>Live Faculty Panel Discussion and Q&amp;A</strong></td>
<td></td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td><strong>Meeting Conclusion and Closing comments from ASENT President</strong></td>
<td></td>
</tr>
</tbody>
</table>
ASENT Leadership

PROGRAM COMMITTEE

CHAIRS
C Anthony Altar, PhD, Chair
Splice Therapeutics
Sharon Tamir, Co-Chair
Karyopharm

COMMITTEE MEMBERS
Carole Burns, PhD
Enrique Carrazana, MD
Marinus Pharmaceuticals
Amy Chappell, MD
Eliam
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Tracy Dixon-Salazar, PhD
Lennox Gastaut Foundation
Debra Ehrlich, MD, MS
NINDS
Stewart Factor, DO
Emory University
Gail Farfel, PhD
Zogenix
Wendy Galpern, MD, PhD
Johnson and Johnson
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
Takeda
Cynthia Rothblum-Oviatt, PhD
RO Scientific
Nancy Santilli, MSN
Human Care Systems
Steve Schachter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont

EX-OFFICIO PROGRAM COMMITTEE MEMBERS
Thomas Sutula, MD, PhD
University of Wisconsin, Madison
Martha Morrell, MD, PhD
NeuroPace, Inc.
Bennett Lavenstein, MD
Children’s National Health System
Amir Tamiz, PhD
NINDS
Robert Hamill, MD
University of Vermont
Barbara Slusher, MAS, PhD
Johns Hopkins University
Michael Rogawski, MD, PhD
University of California, Davis

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE
Thomas Sutula, MD, PhD, PRESIDENT
University of Wisconsin
O’Neill D’Cruz, MD, MBA, FAAN, TREASURER
OD Consulting and Neurological Services, PLLC
Martha Morrell, MD, PAST PRESIDENT
NeuroPace

COMMITTEE MEMBERS
Enrique Carrazana, MD
Marinus Pharmaceuticals
Amy Chappell, MD
Eliam
Stewart A. Factor, DO
Emory University School of Medicine
Gail Farfel, PhD
Zogenix
Toby Ferguson, MD, PhD
Johnson and Johnson
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
Takeda
Cynthia Rothblum-Oviatt, PhD
RO Scientific
Nancy Santilli, MSN
Human Care Systems
Steve Schachter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont

EX-OFFICIO BOARD
Amir Tamiz, PhD
NINDS
Michael Rogawski, MD, PhD
University of California, Davis
M. Maral Mouradian, MD
Rutgers University

David Shoup
Curry Rockefeller Group
Kenneth Sommerville, MD
Sommerville Consulting
Sharon Tamir
Karyopharm
Danilo Vitorovic, MD
University of Vermont
Register Today:
www.eventbrite.com/e/125915487613